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Abstract (158 words) 
Objective: To quantify the impact of acoustic neuroma on the quality-of-life patients in the United Kingdom. 
 
Study design: Online questionnaire survey. 
 
Patients: Members of the British Acoustic Neuroma Association received PANQOL questionnaires. 
 
Results: Of the 880 BANA members contacted, 397 (45.1%) responded, although only 359 had complete 
datasets for analysis. Composite quality-of-life scores were as follows: for microsurgery 58 (SD 35), for 
radiotherapy 56 (SD18), for combination of surgery and radiotherapy 49 (SD 14), and for the observation group 
54 (SD 20). No statistical significance with ANOVA (p=0,532). Mean (SD) composite quality-of-life scores 
were as follows: for follow-up <6 52 (SD 18), for follow-up 6-10 55 (SD 20) and follow-up >10 years 65 (SD 
45). Overall, these values were significantly different compared by ANOVA (p<0.001). Patients with facial 
paralysis showed no statistical significant differences between the different treatment groups.  
 
Conclusions: Short (<6 years) and long-term (>10 years) quality-of-life outcomes show no significant 
differences between the different treatment groups.  
 







Although acoustic neuroma (AN) has a significant impact on patients' overall quality-of-life, comparing 
outcomes in the management of AN can be challenging.  Frequently used study endpoints have included tumour 
growth rate, need for subsequent intervention, facial nerve function, hearing status, tinnitus, and 
vertigo/imbalance. Far fewer studies have evaluated the impact of AN on general well-being and quality-of-life 
(QOL). A systematic review identified 47 studies utilising a variety of patient-reported outcome measures; the 
most frequently used being the Short Form-36 (SF-36) questionnaire and Glasgow Benefit Inventory (GBI) 
[1,2]. Comparison across studies was confounded by the different QOL-tools utilised and none were validated 
specifically for AN. Other studies have focused on specific functional problems such as swallowing, balance and 
facial paralysis and how these complications might affect overall well-being[3]. 
 
The Penn-Acoustic-Neuroma-Quality-of-Life (PANQOL) scale is the only AN specific QOL instrument, which 
is validated for both English and Dutch-speaking patients[4,5]. This 26-item survey assesses patient-perceived 
QOL in seven domains: hearing, balance, facial symptoms, anxiety, energy, pain, and general health. Questions 
on the PANQOL are answered on a scale from 1 to 5. These domain scores are then converted to a scale of 0 to 
100 (lowest to highest QOL) for ease of reporting. A composite quality-of-life (cQOL) score is calculated from 
the averages of individual domain scores and is also reported on a scale of 0 to 100. 
  
The British Acoustic Neuroma Association (BANA) was formed in 1992 as a charity to support people who 
have been diagnosed with AN. BANA members participated in an earlier survey to assess the psychological 
distress, the ways of coping with that stress, and the self-esteem of patients with facial paralysis after AN 
surgery[6]. While there was no association between the level of distress and the grade of facial paralysis, female 
gender and young age correlated with higher level of distress, lower self-esteem and maladaptive coping 
behaviour. However, the overall impact of AN on QOL was not evaluated in this study. 
  
To effectively implement shared-decision making into the AN-management, it is important that patients are 
given information not only about the chances of success and failure, but also about the QOL and distress they 
can expect.  The aim of this study was to evaluate the QOL impact on British AN patients, whether there were 
long-term differences in patient-perceived QOL between different treatment modality and whether QOL 













The BANA board of trustees was involved throughout the design of this cross-sectional, point-in-time 
observational survey[3]. The online link to SurveyMonkey (www.survey monkey.com) was emailed to the 
members of BANA who were on the association emailing list and a reminder was sent 4 weeks later[3]. In 
addition to the PANQOL, the SurveyMonkey online questionnaire surveyed patient demographics (age ranger, 
gender), type of AN-management and when treatment started. No identifying information (such as name, date of 
birth, email or internet protocol address) was collected, thus the responses were completely anonymous.  
 
The forced responses to treatment received for AN were simplified to MS (microsurgery), RT (single or multiple 
radiotherapy/stereotactic radiosurgery/gamma knife), OBS (observation with interval MRI scanning) and 
COMBO (combination of MS and RT). For the MS and RT groups, follow-up defined as years since 
intervention, while follow-up for the OBS group was calculated as years since diagnosis. To assess any temporal 
differences in QOL, each treatment group was subdivided into short-, medium- and long-term follow-up which 
was defined as <6, 6-10 and >10 years follow-up respectively.  
 
Information on tumour size and type of surgical approach (translabyrinthine, middle cranial fossa, retrosigmoid) 
was not collected as it was agreed with the BANA council that such data would not be routinely available from 
the majority of its members.  
 
Calculating PANQOL domain scores 
The analysis of total and domain scores in this study follow previously described in literature[7]. Briefly, 
individual scores were transformed to a 0- to 100-point scale: a response of 1 received 0 points, 2 received 25 
points; 3 received 50 points; 4 received 75 points; and 5 received 100 points. All responses, except item 25, “My 
health is excellent”, were reverse scored so that a higher value indicates better QOL. Domain scores for anxiety, 
facial function, general health, balance, hearing, energy, and pain were obtained by averaging the responses of 
items assigned to the respective domain.  
 
A composite QOL (cQOL) score was calculated as the equal average of the seven domain scores. As such the 
domain scores and the total score could range from 0 to 100, with higher scores indicating better QOL[7]. The 
cQOL data reported here was stratified according to treatment and also to duration of follow-up (<6, 6-10, and 
>10 years). The total PANQOL questionnaire, used formula and categorisation into the seven domains are 
shown in Tables 1 and 2.  
 
Statistical analysis 
The data collected on SurveyMonkey was exported to an Excel (Microsoft, Inc. CA, USA) spreadsheet. Domain 
(anxiety (A), facial symptoms (F), general health (GH), balance (B), hearing (H), energy (E) and pain (P)) scores 
were calculated. These domain scores were then used to calculate a total composite score (cQOL). Statistical 
analysis was performed using the SPSS version 23 software (IBM, New York, USA). Shapiro-Wilk normality 
test were undertaken to determine the distribution of data. The treatment specific PANQOL composite and 
domain scores were compared using unpaired t-test. Within each treatment group, ANOVA and t-test also 


















Of the 880 members contacted, 397 (45.1%) responses were received. Thirty-eight patients (9.6%) were 
excluded for having incomplete data. Thus, a total of 359 (40.8%) BANA members with complete data sets were 
available for analysis in this study (Table 3).  
 
Composite quality-of-life (cQOL) score by treatment modality  
Overall, there were 185 patients in the MS, 94 in the RT, 63 in the OBS and 17 in the COMBO group. The mean 
(standard deviation, SD) cQOL scores for the various groups were as follows: MS 58 (SD 35), RT 56 (SD 18), 
COMBO 49 (SD 14) and OBS 54 (SD 20). These differences were not statistically significant when compared 
by ANOVA (p=0.532). There was also no statistically significant difference (unpaired t-test) when individual 
treatment groups were compared.  
 
Composite quality-of-life (cQOL) score by follow-up period 
When the study cohort was stratified according to follow-up period, there were 198 respondents in the short- (<6 
years), 68 in the medium- (6 – 10 years) and 93 in the long-term (>10 years) follow-up group. Mean (standard 
deviation, SD) cQOL scores were as follows: for short- 52 (SD 18), for medium- 55 (SD 20) and for long-term 
follow-up groups 65 (SD 45). Overall, these values were significantly different compared by ANOVA 
(p<0.001). However, comparing the groups individually with unpaired t-test no significantly difference was 
detected (p=0.053 between short and long-term follow-up). 
 
Table 4 shows cQOL by treatment group and mean years since treatment. No significant difference was found 
within the long-term follow-up.  
 
PANQOL domain scores by treatment modality 
The mean (standard deviation, SD) domain scores of the overall study cohort were as follows (Figure 1): anxiety 
(A) 63 (SD 26), facial function (F) 64 (SD 25), general health (GH) 57 (SD 22), balance (B) 50 (SD 22), hearing 
(H) 45 (SD 23), energy (E) 48 (SD 25) and pain (P) 57 (SD 33).  
 
Both facial and balance domains showed significant differences (unpaired t-test) between the treatment groups. 
In the facial domain, RT (mean QOL 73, SD 22) reported better QOL (with p=0.015) than MS (mean QOL 57, 
SD 26) and also treatment group OBS (mean QOL 74, SD 21) reported better QOL (with p=0.019) than MS 
(mean QOL 57, SD 26). In the balance domain OBS (mean QOL 54, SD 25) reported better QOL (with p=0.046) 
than MS (mean QOL 50, SD 21) and OBS (mean QOL 54, SD 25) reported better QOL (with p=0.038) than 
COMBO (mean QOL 42, SD 18).  
 
PANQOL domain scores by follow-up period 
cQOL scores according to treatment groups, divided by follow-up are illustrated in Figure 2. Amongst the 
follow-up groups, the domain QOL scores were highest in the long-term follow-up group and lowest in the 
short-term follow-up group (except for the facial domain where medium follow-up after treatment scored the 
lowest). Comparing the domain groups individually divided by the follow-up groups with unpaired t-test, 
statistically significant difference was detected within the facial domain. The short-term follow-up group (mean 
QOL 64, SD 23) showed a better QOL (with p=0.002) than the medium-term follow-up group (mean QOL 62, 
SD 28). However, the long-term follow-up QOL (mean QOL 66, SD 28) was significantly higher (p=0.002) than 
the QOL scores within the short-term follow-up group (mean QOL 64, SD 23). The energy domain showed a 
significant difference in QOL (p=0.02) between the short-term follow-up group (mean QOL 45, SD 23) and the 
long-term follow-up (mean QOL 55, SD 26).  
 
PANQOL domain scores by follow-up period 
The mean QOL per domain subdivided by follow-up and treatment is showed in table 5. Looking at the 
differences of QOL divided by treatment and follow-up the only significant differences found were in the facial 
domain >10 years after treatment with higher QOL in the OBS (mean QOL 96, SD5) and RT (mean QOL 82, SD 
18) compared to MS (mean QOL 61, SD 28) with p=0.006 and p=0.031 respectively. Within the domain H, B 






To date, this is the first study focusing on quality of life issues reported by a large cohort of acoustic neuroma 
(AN) patients from across the United Kingdom who are members of BANA.  The data presented here is unique 
as it is not specific to any institution and provides a snapshot of how AN patients are suffering. The result from 
this PANQOL survey corroborate with other studies that acoustic neuroma has an adverse effect on quality of 
life. Even those who were managed conservatively (OBS) reported comparable PANQOL scores as those who 
had either surgery (MS) or radiotherapy (RT).  
 
Unlike previous studies which sampled patients within a single institution, this study has surveyed a larger 
selection of patients across the United Kingdom who were members of BANA.  Anxiety domain scores were 
elevated for all groups which suggests that many patients continue to have significant concerns and unmet needs 
regarding their AN treatment. Interestingly, there was no statistically significant difference in composite QOL 
scores between the treatment cohorts in the individual follow-up intervals although some QOL domains scores 
did differ significantly. Short (<6 years) and long-term (>10 years) quality-of-life outcomes demonstrated no 
statistically significant differences between the different treatment groups. Domain scores of facial and balance 
show a significant difference between MS and RT (p=0.019 and 0.0046, respectively). No statistically significant 
differences were found between the group of patients suffering of facial paralysis both cQOL and facial domain 
QOL were lower compared to the patients without a facial paralysis. In addition, treatment of the facial paralysis 
did not result in a significant higher cQOL/facial domain QOL score. These observations may represent 
differences in treatment outcomes achieved by individual skull base units and available local expertise to deal 
with complications such as facial paralysis and disequilibrium, which underscores the importance of local 
departmental audit and participation in national clinical outcome reviews. 
 
Table 6 shows the number of patients studied and which treatment they received together with the main 
conclusions for the 3 other studies using PANQOL-questionnaires. In contrast to the findings of Robinett et al[2] 
we found no statistically significant differences in cQOL >10 years following treatment.  
 
Our results showed no differences in the balance domain scores when compared between the different treatment 
and follow-up groups. These findings are in contrast to the results of Carlson et al[8], as they showed significant 
differences in the facial, balance, pain and cQOL in multivariate analysis, all in favour of the observation group 
and non-tumour controls. This may be explained by treatment selection bias or the fact that our research designs 
is cross-sectional, with a point-in-time observational study. Possibly the patients who returned the questionnaires 
were by coincidence a selection of patients with certain complaints and outcomes, as only 45.1% returned their 
answers. 
 
Several important considerations warrant attention when assessing the results of this survey. Firstly, the 
membership of BANA is unlikely to be representative of the spectrum of AN-patients in the U.K. Admittedly; 
those who have a good treatment outcome do not remain engaged in support groups such as the BANA but 
return to their daily lives. The distribution of respondents in the treatment groups perhaps reflects the bias from a 
survey such as this. Those patients who maintain active membership are typically those who have experienced 
complications and benefit from the support provided by BANA. Secondly, a group more biased toward a 
negative outcome such as those with facial paralysis or vestibular dysfunction is more likely to respond to a 
survey like this. Third, less than half of eligible respondents (40.8%) returned the questionnaire which was 
comparable to previous surveys. And finally, due to the study design, longitudinal data was not available. 
Therefore, no benefit of treatment could be determined. 
 
These observations may explain why the mean cQOL score in the present study was lower than that reported by 
previous authors. Patients treated with both stereotactic radiosurgery and microsurgery may have had bigger 
tumours and therefore worse QOL-outcomes. As patients were not surveyed prospectively but rather a particular 
point-in-time, temporal trends in QOL were not assessed. Furthermore, data on tumour size was not collected in 
this study and thus how this variable correlate with QOL was not evaluated. Despite these limitations the results 
presented here are valuable as it provides baseline data for audit and provides the basis for larger, prospectively 
database such as the British Skull Base Society Vestibular Schwannoma Audit.  
 
CONCLUSIONS 
Short (<6 years) and long-term (>10 years) quality-of-life outcomes show no significant differences between the 
different treatment groups. Prospective, longitudinal studies utilising the PANQOL would better inform on the 
rehabilitation and support required by AN-patients.  
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Figure 1. Distribution of domain QOL scores according to treatment groups 
 
Figure 2. cQOL scores according to treatment groups, divided by follow-up.  
 
Table 1. PANQOL questionnaire and formula for QOL calculation. 
 
Table 2. PANQOL questionnaire with diversion and points. 
 
Table 3. Summary of demographic and clinical data.  
 
Table 4. Demographics by treatment group and years since treatment 
 
Table 5. Mean QOL subdivided by follow-up group and domain scores. 
 




Figure 1. Distribution of domain QOL scores according to treatment groups 
 
This figure shows the mean quality-of-life (QOL) scores for each domain score A (anxiety), F (facial symptoms), GH (general health), B 






Figure 2. cQOL scores according to treatment groups, divided by follow-up.  
 
 










Disagree Neutral Agree Strongly 
agree 
1. 1. Hearing loss has affected my personal 
relationships. 
1 2 3 4 5 
2. 2. I have difficulty carrying on a conversation 
because of hearing loss. 
1 2 3 4 5 
3. 3. My concentration is affected by ringing, hissing 
or other noises in my ears. 
1 2 3 4 5 
4. 4. I have significant problems with dizziness. 1 2 3 4 5 
5. 5. I feel unsteady or off balance. 1 2 3 4 5 
6. 6. I feel a sense of whirling or falling when standing 
or walking. 
1 2 3 4 5 
7. 7. Because of dizziness or imbalance, I have 
difficulties with changing direction while walking. 
1 2 3 4 5 
8. 8. I have difficulties walking around my house in the 
dark. 
1 2 3 4 5 
9. 9. Because of balance problems, I am afraid people 
will think I am intoxicated. 
1 2 3 4 5 
10. 10. I act differently around people because of 
problems moving my face. 
1 2 3 4 5 
11. 11. I have discomfort, itching or excessive tearing in 
one of my eyes. 
1 2 3 4 5 
12. 12. My speech has been affected by problems with 
my face. 
1 2 3 4 5 
13. 13. I accomplish less than I would like because of 
my diagnosis of acoustic neuroma. 
1 2 3 4 5 
14. 14. I have problems with head pain on the side of 
my acoustic neuroma tumor. 
1 2 3 4 5 
15. 15. I get a sort of frightened feeling as if something 
awful is about to happen. 
1 2 3 4 5 
16. 16. Worrying thoughts go through my mind. 1 2 3 4 5 
17. 17. I feel as if I am slowed down. 1 2 3 4 5 
18. 18. I get a sort of frightened feeling like “butterflies” 
in the stomach. 
1 2 3 4 5 
19. 19. I get sudden feelings of panic. 1 2 3 4 5 
20. 20. I often feel isolated as a result of my diagnosis 
of acoustic neuroma. 
1 2 3 4 5 
21. 21. I have had difficulty concentrating on things, 
like reading a newspaper or watching television. 
1 2 3 4 5 
22. 22. I have become more impatient. 1 2 3 4 5 
23. 23. I am lacking in energy or vitality. 1 2 3 4 5 
24. 24. I have difficulty remembering things. 1 2 3 4 5 
25. 25. My health is excellent. 1 2 3 4 5 
26. 26. I expect my health to get worse in the coming 
year. 
1 2 3 4 5 
 
Domains: 
     
Anxiety Items 15,16,18,19    
Facial dysfunction Items 10,11,12    
General health Items 25,26    
Balance  Items 4,5,6,7,8,9    
Hearing loss Items 1,2,3,20    
Energy Items 13,17,21,22,23,24    
Pain Item 14 
 
   
Individual scores will be transformed to a 0- to 100-point scale.  
First all scores will be reversed, except item 25, so that a higher score will indicate better QOL.  
 
A response of 1 will receive 0 points, 2, 25 points; 3, 50 points; 4, 75 points; and 5, 100 points. 
 
Domain scores are obtained by averaging the responses of items assigned to the domain. A total score is calculated as the 
equal average of the 7 domain scores.  








Disagree Neutral Agree Strongly 
agree 
27. 1. Hearing loss has affected my personal 
relationships. 
100 75 50 25 0 
28. 2. I have difficulty carrying on a conversation 
because of hearing loss. 
100 75 50 25 0 
29. 3. My concentration is affected by ringing, hissing 
or other noises in my ears. 
100 75 50 25 0 
30. 4. I have significant problems with dizziness. 100 75 50 25 0 
31. 5. I feel unsteady or off balance. 100 75 50 25 0 
32. 6. I feel a sense of whirling or falling when standing 
or walking. 
100 75 50 25 0 
33. 7. Because of dizziness or imbalance, I have 
difficulties with changing direction while walking. 
100 75 50 25 0 
34. 8. I have difficulties walking around my house in the 
dark. 
100 75 50 25 0 
35. 9. Because of balance problems, I am afraid people 
will think I am intoxicated. 
100 75 50 25 0 
36. 10. I act differently around people because of 
problems moving my face. 
100 75 50 25 0 
37. 11. I have discomfort, itching or excessive tearing in 
one of my eyes. 
100 75 50 25 0 
38. 12. My speech has been affected by problems with 
my face. 
100 75 50 25 0 
39. 13. I accomplish less than I would like because of 
my diagnosis of acoustic neuroma. 
100 75 50 25 0 
40. 14. I have problems with head pain on the side of 
my acoustic neuroma tumor. 
100 75 50 25 0 
41. 15. I get a sort of frightened feeling as if something 
awful is about to happen. 
100 75 50 25 0 
42. 16. Worrying thoughts go through my mind. 100 75 50 25 0 
43. 17. I feel as if I am slowed down. 100 75 50 25 0 
44. 18. I get a sort of frightened feeling like “butterflies” 
in the stomach. 
100 75 50 25 0 
45. 19. I get sudden feelings of panic. 100 75 50 25 0 
46. 20. I often feel isolated as a result of my diagnosis 
of acoustic neuroma. 
100 75 50 25 0 
47. 21. I have had difficulty concentrating on things, 
like reading a newspaper or watching television. 
100 75 50 25 0 
48. 22. I have become more impatient. 100 75 50 25 0 
49. 23. I am lacking in energy or vitality. 100 75 50 25 0 
50. 24. I have difficulty remembering things. 100 75 50 25 0 
51. 25. My health is excellent. 0 25 50 75 100 
52. 26. I expect my health to get worse in the coming 
year. 
100 75 50 25 0 
 
Domain scores: 
     
Anxiety ((15 + 16 + 18 + 19)/4)    
Facial dysfunction ((10 + 11 + 12)/3)    
General health ((25 + 26)/2)    
Balance  ((4 + 5 + 6 + 7 + 8 + 9)/6)    
Hearing loss ((1 + 2 + 3 + 20)/4)    
Energy ((13 + 17 + 21 + 22 + 23 + 24)/6)   
Pain ((14)/1) 
 
Total score: (sum of all domain outcomes)/7 






Table 3. Summary of demographic and clinical data. 
 
  N (%) 
Sex   




Age distribution (year)   
 <21 0  
 21-30 1 (0.3) 
 31-40 26 (7.2) 
 41-50 53 (14.8) 
 51-60 102 (28.4) 
 61-70 137 (38.2) 
 71-80 34 (9.5) 




Follow-up after treatment Mean 7.0 







   
Treatment for acoustic neuroma   
 Surgery (single or multiple operations) 185 (51.5) 
 Radiation (single or multiple radiotherapy/stereotactic radiosurgery/gamma knife) 94 (26.2) 
 Combination of surgery and radiation treatment 17 (4.7) 






Table 4. Demographics by treatment group and years since treatment 
 
 




  RT (n=94) 
 




































2.2 8.2 16.9 
 
2.0 7.4 16.6 
 
2.3 8.5 13.3 
 
1.7 8.1 12.0 
Mean cQOL 53.9 49.5 66.7 
 
52.2 62.0 62.1 
 
48.5 42.1 57.2 
 
49.8 63.6 75.2 
 
MS = microsurgery, RT = Radiation (single or multiple radiotherapy/stereotactic radiosurgery/gamma knife), COMBO = Combination of 





Table 5. Mean QOL subdivided by follow-up group and domain scores. 
  
Follow-up Treatment Domain A F GH B H E P 
 

















 RT (n=62)  61 59 55 45 40 48 48 
 COMBO (n=10)  62 55 55 43 44 35 45 
 OBS (n=46)  52 71 46 50 41 42 48 
          
6-10 years MS (n=33)  59 47 53 43 43 42 60 
 RT (n=18)  68 81 56 58 49 61 61 
 COMBO (n=4)  58 48 47 36 33 42 31 
 OBS (n=13)  66 79 64 57 49 61 69 
          
>10 years MS (n=73)  73 61 64 55 52 54 64 
 RT (n=14)  66 82 57 56 52 55 68 
 COMBO (n=3)  75 69 50 44 40 56 67 
 OBS (n=4)  84 96 59 85 45 69 88 
 
MS = microsurgery, RT = Radiation (single or multiple radiotherapy/stereotactic radiosurgery/gamma knife), COMBO = Combination of 
surgery and radiation treatment, OBS = Interval scanning (not had surgery or radiation therapy), QOL = Quality-of-life. Domain A (anxiety), 
F (facial symptoms), GH (general health), B (balance), H (hearing), E (energy) and P (pain). The highest value within the domain score 







Table 6. Summary of quality of life studies utilising PANQOL. 
 










Key findings PANQOL scores 
McLaughlin et al 201410 186  MS 39 (21%) 
RT 49 (26.3%) 
OBS 98 (52.7%) 
 
Mean 2.6  No significant difference 






Robinett et al 20142 279 MS 157 (56.3%) 
RT 43 (15.4%) 
OBS 79 (28.3%) 
 
 
Mean 7.9  Long-term (>5 years) QOL 
outcomes by PANQOL 
show no significant 
differences between 
treatment groups.  















Carlson et al 20158 642 MS 144  (22.4%) 
RT 247 (38.5%) 
OBS 148 (23%) 
Non tumour controls 103 
Mean 7.7 Significant differences:  
MS vs. RT (p=0.004) 






This study  
 
359 MS 185 (51.5%) 
RT 94 (26.2%) 
COMBO 17 (4.7%) 
OBS 63 (17.5%) 
Mean 7.0 Significant differences: 
Facial domain QOL: 
RT vs. MS (p=0.015) 
OBS vs. MS (p=0.019) 
 
Balance domain QOL : 
OBS vs. MS (p=0.046) 
OBS vs. COMBO 
(p=0.038) 
 
Long-term vs. short-term 
follow-up groups: 
Significant differences for 
Facial and Energy domain 












Follow-up >10 years: 
MS 67 
RT 62 
COMBO 57 
OBS 75 
 
 
 
